

Supplemental Information: Online Resource 2 – Supplemental Results

European Journal of Clinical Pharmacology

Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study

Vladimir Trkulja, Ivan Kodvanj

Corresponding author: Vladimir Trkulja, MD, PhD
Department of Pharmacology
Zagreb University School of Medicine
Šalata 11, 10000 Zagreb, CROATIA
Fax: +385-1-49-200-49
Phone: +385-98-325-307
E-mail: vladimir.trkulja@mef.hr

Contents

Table S5. Study 1: Matching covariates in Cohort A and Cohort B before and after matching

Table A6. Study 1: Matching covariates in Cohort A and Cohort C before and after matching

Table S7. Study 1: Matching covariates in Cohort B and Cohort C before and after matching

Table S8. Study 2: Matching covariates in Cohort Fluvoxamine and Cohort Paroxetine before and after matching

Table S5 Study 1: Matching covariates in Cohort A and Cohort B before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

Characteristics	Before matching			After matching		
	Cohort A	Cohort B	d	Cohort A	Cohort B	d
n	1016	95984		749	31336	
Age						
[16,21)	36 (3.5)	1389 (1.4)	0.135	17.5 (2.3)	733.5 (2.3)	0.000
[21,26)	31 (3.1)	2142 (2.2)	0.051	27.7 (3.7)	1160.3 (3.7)	0.000
[26,31)	45 (4.4)	2869 (3.0)	0.076	41.6 (5.5)	1738.4 (5.5)	0.000
[31,36)	51 (5.0)	4034 (4.2)	0.039	57.8 (7.7)	2418.2 (7.7)	0.000
[36,41)	85 (8.4)	6002 (6.3)	0.081	85.7 (11.4)	3585.3 (11.4)	0.000
[41,46)	83 (8.2)	7706 (8.0)	0.005	98.5 (13.1)	4120.5 (13.1)	0.000
[46,51)	96 (9.4)	9166 (9.5)	-0.003	119.1 (15.9)	4980.9 (15.9)	0.000
[51,56)	106 (10.4)	10689 (11.1)	-0.023	115.9 (15.5)	4850.1 (15.5)	0.000
[56,61)	111 (10.9)	11457 (11.9)	-0.032	88.9 (11.9)	3720.1 (11.9)	0.000
[61,66)	90 (8.9)	10697 (11.1)	-0.076	56.0 (7.5)	2345.0 (7.5)	0.000
[66,71)	68 (6.7)	8561 (8.9)	-0.083	17.0 (2.3)	713.0 (2.3)	0.000
[71,76)	73 (7.2)	6715 (7.0)	0.007	12.5 (1.7)	521.5 (1.7)	0.000
[76,81)	45 (4.4)	5466 (5.7)	-0.058	3.7 (0.5)	153.3 (0.5)	0.000
[81,86)	55 (5.4)	4924 (5.1)	0.013	5.6 (0.8)	236.4 (0.8)	0.000
[86,91)	35 (3.4)	2984 (3.1)	0.019	1.3 (0.2)	55.7 (0.2)	0.000
[91,96)	5 (0.5)	1011 (1.1)	-0.064	0.1 (0.0)	3.9 (0.0)	0.000
[96,101)	1 (0.1)	166 (0.2)	-0.020	0.0 (0.0)	0.0 (0.0)	0.000
[101,106)	0 (0.0)	6 (0.0)	-0.011	0.0 (0.0)	0.0 (0.0)	0.000
[106,111)	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
Sex						
Male	441 (43.4)	33604 (35.0)	0.173	221.0 (29.5)	9245.0 (29.5)	0.000
Female	575 (56.6)	62380 (65.0)	-0.173	528.0 (70.5)	22091.0 (70.5)	0.000
Vaccination status						
1/1, >90 days	0 (0.0)	1 (0.0)	-0.005	0.0 (0.0)	0.0 (0.0)	0.000
1/1, <14 days	0 (0.0)	13 (0.0)	-0.016	0.0 (0.0)	0.0 (0.0)	0.000
1/1, 14-90 days	0 (0.0)	8 (0.0)	-0.013	0.0 (0.0)	0.0 (0.0)	0.000
Not vaccinated	958 (94.3)	90719 (94.5)	-0.010	747.6 (99.8)	31275.4 (99.8)	0.000
1/2, >90 days	0 (0.0)	28 (0.0)	-0.024	0.0 (0.0)	0.0 (0.0)	0.000
1/2, <14 days	23 (2.3)	1724 (1.8)	0.033	0.4 (0.0)	15.6 (0.0)	0.000
1/2, 14-90 days	27 (2.7)	2431 (2.5)	0.008	1.0 (0.1)	41.0 (0.1)	0.000
2/2, >90 days	1 (0.1)	237 (0.2)	-0.036	0.0 (0.0)	0.0 (0.0)	0.000
2/2, <14 days	0 (0.0)	298 (0.3)	-0.079	0.0 (0.0)	0.0 (0.0)	0.000
2/2, 14-90 days	7 (0.7)	525 (0.5)	0.018	0.1 (0.0)	3.9 (0.0)	0.000
Period						
Up to January 9, 2021	591 (58.2)	55623 (58.0)	0.004	456.8 (61.0)	19109.2 (61.0)	0.000
January 10 to July 15, 2021	408 (40.2)	39112 (40.7)	-0.012	290.4 (38.8)	12147.6 (38.8)	0.000
After July 15, 2021	17 (1.7)	1249 (1.3)	0.031	1.9 (0.3)	79.1 (0.3)	0.000
CCI						
0	609 (59.9)	55122 (57.4)	0.051	706.0 (94.3)	29538.0 (94.3)	0.000
1-2	293 (28.8)	31229 (32.5)	-0.080	42.5 (5.7)	1776.5 (5.7)	0.000
3-4	86 (8.5)	7375 (7.7)	0.029	0.5 (0.1)	21.5 (0.1)	0.000
>=5	28 (2.8)	2258 (2.4)	0.026	0.0 (0.0)	0.0 (0.0)	0.000
Comorbidities						
Atrial fibrillation/undulation	61 (6.0)	5850 (6.1)	-0.004	1.1 (0.1)	44.9 (0.1)	0.000
Autoimmune disease	112 (11.0)	13295 (13.9)	-0.086	17.5 (2.3)	732.5 (2.3)	0.000
Cancer	58 (5.7)	7569 (7.9)	-0.087	2.6 (0.4)	110.4 (0.4)	0.000
Congestive heart failure	30 (3.0)	3907 (4.1)	-0.061	0.3 (0.0)	10.7 (0.0)	0.000
COPD	112 (11.0)	12808 (13.3)	-0.071	18.5 (2.5)	775.5 (2.5)	0.000
IHD or CVD	149 (14.7)	12803 (13.3)	0.038	6.4 (0.9)	268.6 (0.9)	0.000
Renal disease	23 (2.3)	2067 (2.2)	0.008	0.0 (0.0)	0.0 (0.0)	0.000
Diabetes + complications	19 (1.9)	1611 (1.7)	0.015	0.0 (0.0)	2.0 (0.0)	0.000
Diabetes w/o complications	165 (16.2)	15155 (15.8)	0.012	13.0 (1.7)	544.0 (1.7)	0.000
Dementia	37 (3.6)	2356 (2.5)	0.069	0.5 (0.1)	21.5 (0.1)	0.000
Immunocompromised	14 (1.4)	1559 (1.6)	-0.020	0.1 (0.0)	2.9 (0.0)	0.000
RAAS inhibitors	293 (28.8)	30443 (31.7)	-0.063	88.0 (11.8)	3682.0 (11.8)	0.000
Diuretics	125 (12.3)	14193 (14.8)	-0.073	7.2 (1.0)	300.8 (1.0)	0.000
F10-F19	28 (2.8)	2650 (2.8)	0.000	1.1 (0.1)	43.9 (0.1)	0.000
F20-F29	119 (11.7)	5306 (5.5)	0.222	18.7 (2.5)	780.3 (2.5)	0.000
F30-F39	446 (43.9)	20856 (21.7)	0.486	121.7 (16.3)	5092.3 (16.3)	0.000

F40-F48	692 (68.1)	71242 (74.2)	-0.135	655.1 (87.5)	27408.9 (87.5)	0.000
Any of F04-F09, F50-F59, F60-F69, F70-F79, F80-F89, F90-F98	229 (22.5)	19431 (20.2)	0.056	47.6 (6.4)	1992.4 (6.4)	0.000
COVID-related hospitalization	34 (3.3)	3128 (3.3)	0.019	5.3 (0.7)	160.7 (0.5)	0.024
All-cause 30-day hospitalization	127 (12.5)	11266 (11.7)	0.023	62.1 (8.3)	1378.7 (4.4)	0.119
COVID-related death	38 (3.7)	4261 (4.4)	-0.035	2.8 (0.4)	161.8 (0.5)	-0.007

Table S6 Study 1: Matching covariates in Cohort A and Cohort C before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

Characteristics	Before matching			After matching		
	Cohort A	Cohort C	d	Cohort A	Cohort C	d
n	1016	275804		866	222792	
Age						
[16,21)	36 (3.5)	21127 (7.7)	-0.180	73.7 (8.5)	18966.3 (8.5)	0.000
[21,26)	31 (3.1)	26298 (9.5)	-0.269	92.9 (10.7)	23895.1 (10.7)	0.000
[26,31)	45 (4.4)	29134 (10.6)	-0.235	102.0 (11.8)	26237.0 (11.8)	0.000
[31,36)	51 (5.0)	30974 (11.2)	-0.229	107.4 (12.4)	27640.6 (12.4)	0.000
[36,41)	85 (8.4)	32123 (11.6)	-0.109	114.0 (13.2)	29325.0 (13.2)	0.000
[41,46)	83 (8.2)	29678 (10.8)	-0.089	102.1 (11.8)	26259.9 (11.8)	0.000
[46,51)	96 (9.4)	24825 (9.0)	0.015	81.5 (9.4)	20961.5 (9.4)	0.000
[51,56)	106 (10.4)	22057 (8.0)	0.084	70.2 (8.1)	18058.8 (8.1)	0.000
[56,61)	111 (10.9)	19061 (6.9)	0.141	54.6 (6.3)	14040.4 (6.3)	0.000
[61,66)	90 (8.9)	14962 (5.4)	0.134	35.5 (4.1)	9121.5 (4.1)	0.000
[66,71)	68 (6.7)	10422 (3.8)	0.131	17.3 (2.0)	4454.7 (2.0)	0.000
[71,76)	73 (7.2)	6473 (2.3)	0.229	9.3 (1.1)	2398.7 (1.1)	0.000
[76,81)	45 (4.4)	4138 (1.5)	0.173	2.4 (0.3)	611.6 (0.3)	0.000
[81,86)	55 (5.4)	2820 (1.0)	0.251	2.5 (0.3)	646.5 (0.3)	0.000
[86,91)	35 (3.4)	1274 (0.5)	0.217	0.6 (0.1)	166.4 (0.1)	0.000
[91,96)	5 (0.5)	362 (0.1)	0.065	0.0 (0.0)	8.0 (0.0)	0.000
[96,101)	1 (0.1)	75 (0.0)	0.028	0.0 (0.0)	0.0 (0.0)	0.000
[101,106)	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
[106,111)	0 (0.0)	1 (0.0)	-0.003	0.0 (0.0)	0.0 (0.0)	0.000
Sex						
Male	441 (43.4)	144548 (52.4)	-0.181	434.8 (50.2)	111856.2 (50.2)	0.000
Female	575 (56.6)	131256 (47.6)	0.181	431.2 (49.8)	110935.8 (49.8)	0.000
Vaccination status						
1/1, >90 days	0 (0.0)	1 (0.0)	-0.003	0.0 (0.0)	0.0 (0.0)	0.000
1/1, <14 days	0 (0.0)	38 (0.0)	-0.017	0.0 (0.0)	0.0 (0.0)	0.000
1/1, 14-90 days	0 (0.0)	43 (0.0)	-0.018	0.0 (0.0)	0.0 (0.0)	0.000
Not vaccinated	958 (94.3)	269392 (97.7)	-0.173	864.1 (99.8)	222315.9 (99.8)	0.000
1/2, >90 days	0 (0.0)	16 (0.0)	-0.011	0.0 (0.0)	0.0 (0.0)	0.000
1/2, <14 days	23 (2.3)	2667 (1.0)	0.103	0.8 (0.1)	207.2 (0.1)	0.000
1/2, 14-90 days	27 (2.7)	2645 (1.0)	0.128	1.0 (0.1)	253.0 (0.1)	0.000
2/2, >90 days	1 (0.1)	201 (0.1)	0.009	0.0 (0.0)	0.0 (0.0)	0.000
2/2, <14 days	0 (0.0)	205 (0.1)	-0.039	0.0 (0.0)	0.0 (0.0)	0.000
2/2, 14-90 days	7 (0.7)	596 (0.2)	0.070	0.1 (0.0)	15.9 (0.0)	0.000
Period						
Up to January 9, 2021	591 (58.2)	163836 (59.4)	-0.025	535.9 (61.9)	137861.1 (61.9)	0.000
January 10 to July 15, 2021	408 (40.2)	106379 (38.6)	0.032	324.0 (37.4)	83354.0 (37.4)	0.000
After July 15, 2021	17 (1.7)	5589 (2.0)	-0.026	6.1 (0.7)	1576.9 (0.7)	0.000
CCI						
0	609 (59.9)	230007 (83.4)	-0.539	819.6 (94.6)	210856.4 (94.6)	0.000
1-2	293 (28.8)	40370 (14.6)	0.350	45.9 (5.3)	11804.1 (5.3)	0.000
3-4	86 (8.5)	4380 (1.6)	0.319	0.5 (0.1)	127.5 (0.1)	0.000
>=5	28 (2.8)	1047 (0.4)	0.192	0.0 (0.0)	4.0 (0.0)	0.000
Comorbidities						
Atrial fibrillation/undulation	61 (6.0)	4017 (1.5)	0.242	0.7 (0.1)	190.3 (0.1)	0.000
Autoimmune disease	112 (11.0)	14281 (5.2)	0.215	20.8 (2.4)	5361.2 (2.4)	0.000
Cancer	58 (5.7)	7109 (2.6)	0.158	2.7 (0.3)	686.3 (0.3)	0.000
Congestive heart failure	30 (3.0)	2149 (0.8)	0.161	0.1 (0.0)	16.9 (0.0)	0.000
COPD	112 (11.0)	17171 (6.2)	0.172	22.8 (2.6)	5872.2 (2.6)	0.000
IHD or CVD	149 (14.7)	8240 (3.0)	0.421	3.5 (0.4)	912.5 (0.4)	0.000
Renal disease	23 (2.3)	1334 (0.5)	0.153	0.0 (0.0)	6.0 (0.0)	0.000
Diabetes + complications	19 (1.9)	1131 (0.4)	0.138	0.1 (0.0)	15.9 (0.0)	0.000
Diabetes w/o complications	165 (16.2)	15706 (5.7)	0.342	15.8 (1.8)	4057.2 (1.8)	0.000
Dementia	37 (3.6)	2482 (0.9)	0.016	0.9 (0.1)	222.8 (0.1)	0.000
Immunocompromised	14 (1.4)	1375 (0.5)	0.091	0.1 (0.0)	19.9 (0.0)	0.000
RAAS inhibitors	293 (28.8)	30386 (11.0)	0.458	49.1 (5.7)	12637.9 (5.7)	0.000
Diuretics	125 (12.3)	9719 (3.5)	0.330	4.6 (0.5)	1189.4 (0.5)	0.000
COVID-related hospitalization	34 (3.3)	2590 (0.9)	0.714	5.8 (0.7)	874.1 (0.4)	0.038
All-cause 30-day hospitalization	127 (12.5)	14297 (5.2)	0.260	46.2 (5.3)	7475.4 (3.4)	0.070
COVID-related death	38 (3.7)	2898 (1.1)	0.177	3.6 (0.4)	752.1 (0.3)	0.005

Table S7. Study 1: Matching covariates in Cohort B and Cohort C before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

Characteristics	Before matching			After matching		
	Cohort B	Cohort C	d	Cohort B	Cohort C	d
n	95984	275804		82323	268778	
Age						
[16,21)	1389 (1.4)	21127 (7.7)	-0.301	5212.5 (6.3)	17018.5 (6.3)	0.000
[21,26)	2142 (2.2)	26298 (9.5)	-0.314	6606.9 (8.0)	21571.1 (8.0)	0.000
[26,31)	2869 (3.0)	29134 (10.6)	-0.305	7427.3 (9.0)	24249.7 (9.0)	0.000
[31,36)	4034 (4.2)	30974 (11.2)	-0.266	8125.6 (9.9)	26529.4 (9.9)	0.000
[36,41)	6002 (6.3)	32123 (11.6)	-0.190	8834.9 (10.7)	28845.1 (10.7)	0.000
[41,46)	7706 (8.0)	29678 (10.8)	-0.094	8629.7 (10.5)	28175.3 (10.5)	0.000
[46,51)	9166 (9.5)	24825 (9.0)	0.019	7799.4 (9.5)	25464.6 (9.5)	0.000
[51,56)	10689 (11.1)	22057 (8.0)	0.107	7444.0 (9.0)	24304.0 (9.0)	0.000
[56,61)	11457 (11.9)	19062 (6.9)	0.173	6816.8 (8.3)	22256.2 (8.3)	0.000
[61,66)	10697 (11.1)	14962 (5.4)	0.209	5542.7 (6.7)	18096.3 (6.7)	0.000
[66,71)	8561 (8.9)	10422 (3.8)	0.212	3882.8 (4.7)	12677.2 (4.7)	0.000
[71,76)	6715 (7.0)	6473 (2.3)	0.222	2478.4 (3.0)	8091.6 (3.0)	0.000
[76,81)	5466 (5.7)	4138 (1.5)	0.227	1590.7 (1.9)	5193.3 (1.9)	0.000
[81,86)	4924 (5.1)	2820 (1.0)	0.240	1194.9 (1.5)	3901.1 (1.5)	0.000
[86,91)	2984 (3.1)	1274 (0.5)	0.201	574.5 (0.7)	1875.5 (0.7)	0.000
[91,96)	1011 (1.1)	362 (0.1)	0.120	143.5 (0.2)	468.5 (0.2)	0.000
[96,101)	166 (0.2)	75 (0.0)	0.046	18.5 (0.0)	60.5 (0.0)	0.000
[101,106)	6 (0.0)	0 (0.0)	0.011	0.0 (0.0)	0.0 (0.0)	0.000
[106,111)	0 (0.0)	1 (0.0)	-0.003	0.0 (0.0)	0.0 (0.0)	0.000
Sex						
Male	33604 (35.0)	144549 (52.4)	-0.356	39525.9 (48.0)	129049.1 (48.0)	0.000
Female	62380 (65.0)	131256 (47.6)	0.356	42797.1 (52.0)	139728.9 (52.0)	0.000
Vaccination status						
1/1, >90 days	1 (0.0)	1 (0.0)	0.003	0.0 (0.0)	0.0 (0.0)	0.000
1/1, <14 days	13 (0.0)	38 (0.0)	0.000	0.5 (0.0)	1.5 (0.0)	0.000
1/1, 14-90 days	8 (0.0)	43 (0.0)	-0.007	1.6 (0.0)	5.4 (0.0)	0.000
Not vaccinated	90719 (94.5)	269393 (97.7)	-0.164	80697.9 (98.0)	263472.1 (98.0)	0.000
1/2, >90 days	28 (0.0)	16 (0.0)	0.018	0.0 (0.0)	0.0 (0.0)	0.000
1/2, <14 days	1724 (1.8)	2667 (1.0)	0.071	701.5 (0.9)	2290.5 (0.9)	0.000
1/2, 14-90 days	2431 (2.5)	2645 (1.0)	0.120	745.6 (0.9)	2434.4 (0.9)	0.000
2/2, >90 days	237 (0.2)	201 (0.1)	0.044	16.6 (0.0)	54.4 (0.0)	0.000
2/2, <14 days	298 (0.3)	205 (0.1)	0.054	33.3 (0.0)	108.7 (0.0)	0.000
2/2, 14-90 days	525 (0.5)	596 (0.2)	0.054	125.9 (0.2)	411.1 (0.2)	0.000
Period						
Up to January 9, 2021	55623 (58.0)	163836 (59.4)	-0.030	49131.1 (59.7)	160408.9 (59.7)	0.000
January 10 to July 15, 2021	39112 (40.7)	106380 (38.6)	0.045	31841.2 (38.7)	103958.8 (38.7)	0.000
After July 15, 2021	1249 (1.3)	5589 (2.0)	-0.057	1350.8 (1.6)	4410.2 (1.6)	0.000
CCI						
0	55122 (57.4)	230007 (83.4)	-0.593	66386.5 (80.6)	216746.5 (80.6)	0.000
1-2	31229 (32.5)	40371 (14.6)	0.431	14686.1 (17.8)	47948.9 (17.8)	0.000
3-4	7375 (7.7)	4380 (1.6)	0.293	1125.7 (1.4)	3675.3 (1.4)	0.000
>=5	2258 (2.4)	1047 (0.4)	0.171	124.7 (0.2)	407.3 (0.2)	0.000
Comorbidities						
Atrial fibrillation/undulation	5850 (6.1)	4017 (1.5)	0.245	1131.6 (1.4)	3694.4 (1.4)	0.000
Autoimmune disease	13295 (13.9)	14282 (5.2)	0.299	5214.2 (6.3)	17023.8 (6.3)	0.000
Cancer	7569 (7.9)	7109 (2.6)	0.240	2367.5 (2.9)	7729.5 (2.9)	0.000
Congestive heart failure	3907 (4.1)	2149 (0.8)	0.215	435.2 (0.5)	1420.8 (0.5)	0.000
COPD	12808 (13.3)	17172 (6.2)	0.241	5618.2 (6.8)	18342.8 (6.8)	0.000
IHD or CVD	12803 (13.3)	8240 (3.0)	0.385	3081.4 (3.7)	10060.6 (3.7)	0.000
Renal disease	2067 (2.2)	1334 (0.5)	0.147	152.4 (0.2)	497.6 (0.2)	0.000
Diabetes + complications	1611 (1.7)	1131 (0.4)	0.125	235.6 (0.3)	769.4 (0.3)	0.000
Diabetes w/o complications	15155 (15.8)	15706 (5.7)	0.330	5420.7 (6.6)	17698.3 (6.6)	0.000
Dementia	2356 (2.5)	2482 (0.9)	0.023	82.3(0.1)	268.8 (0.1)	0.000
Immunocompromised	1559 (1.6)	1375 (0.5)	0.110	265.0 (0.3)	865.0 (0.3)	0.000
RAAS inhibitors	30443 (31.7)	30386 (11.0)	0.522	11825.3 (14.4)	38608.7 (14.4)	0.000
Diuretics	14193 (14.8)	9719 (3.5)	0.398	3577.6 (4.3)	11680.4 (4.3)	0.000
COVID-related hospitalization	3128 (3.3)	2590 (0.9)	0.699	997.1 (1.21)	2754.9 (1.0)	0.018
All-cause 30-day hospitalization	11266 (11.7)	14297 (5.2)	0.237	5080.1 (6.2)	15581.0 (5.8)	0.014
COVID-related death	4261 (4.4)	2898 (1.1)	0.209	1191.7 (1.4)	3295.2 (1.2)	0.014

Table S8. Study 2: Matching covariates in Cohort Fluvoxamine and Cohort Paroxetine before [count (%)] and after matching [weighted count (%)] with standardized differences (d).

Characteristics	Before matching			After matching		
	Cohort Flu	Cohort Par	d	Cohort Flu	Cohort Par	d
n	994	1796		334	535	
Age						
[16,21)	35 (3.5)	5 (0.3)	0.239	3.5 (1.0)	5.5 (1.0)	0.000
[21,26)	29 (2.9)	20 (1.1)	0.129	9.2 (2.8)	14.8 (2.8)	0.000
[26,31)	44 (4.4)	38 (2.1)	0.130	10.4 (3.1)	16.6 (3.1)	0.000
[31,36)	51 (5.1)	63 (3.5)	0.080	23.4 (7.0)	37.6 (7.0)	0.000
[36,41)	84 (8.5)	121 (6.7)	0.065	40.7 (12.2)	65.3 (12.2)	0.000
[41,46)	80 (8.0)	160 (8.9)	-0.031	51.5 (15.4)	82.5 (15.4)	0.000
[46,51)	95 (9.6)	197 (11.0)	-0.047	58.4 (17.5)	93.6 (17.5)	0.000
[51,56)	102 (10.3)	202 (11.2)	-0.032	55.0 (16.5)	88.0 (16.5)	0.000
[56,61)	108 (10.9)	210 (11.7)	-0.026	36.1 (10.8)	57.9 (10.8)	0.000
[61,66)	88 (8.9)	215 (12.0)	-0.102	27.3 (8.2)	43.7 (8.2)	0.000
[66,71)	68 (6.8)	160 (8.9)	-0.077	9.6 (2.9)	15.4 (2.9)	0.000
[71,76)	71 (7.1)	153 (8.5)	-0.051	5.0 (1.5)	8.0 (1.5)	0.000
[76,81)	44 (4.4)	107 (6.0)	-0.069	3.1 (0.9)	4.9 (0.9)	0.000
[81,86)	55 (5.5)	93 (5.2)	0.016	0.8 (0.2)	1.2 (0.2)	0.000
[86,91)	34 (3.4)	40 (2.2)	0.072	0.0 (0.0)	0.0 (0.0)	0.000
[91,96)	5 (0.5)	12 (0.7)	-0.022	0.0 (0.0)	0.0 (0.0)	0.000
[96,101)	1 (0.1)	0 (0.0)	0.045	0.0 (0.0)	0.0 (0.0)	0.000
[101,106)	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
[106,111)	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
Sex						
Male	431 (43.4)	564 (31.4)	0.249	111.8 (33.5)	179.2 (33.5)	0.000
Female	563 (56.6)	1232 (68.6)	-0.249	222.2 (66.5)	355.8 (66.5)	0.000
Vaccination status						
1/1, >90 days	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
1/1, <14 days	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
1/1, 14-90 days	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
Not vaccinated	936 (94.2)	1697 (94.5)	-0.014	331.7 (99.3)	531.3 (99.3)	0.000
1/2, >90 days	0 (0.0)	0 (0.0)	0.000	0.0 (0.0)	0.0 (0.0)	0.000
1/2, <14 days	23 (2.3)	27 (1.5)	0.059	0.0 (0.0)	0.0 (0.0)	0.000
1/2, 14-90 days	27 (2.7)	51 (2.8)	-0.008	1.5 (0.5)	2.5 (0.5)	0.000
2/2, >90 days	1 (0.1)	5 (0.3)	-0.041	0.0 (0.0)	0.0 (0.0)	0.000
2/2, <14 days	0 (0.0)	4 (0.2)	-0.067	0.0 (0.0)	0.0 (0.0)	0.000
2/2, 14-90 days	7 (0.7)	12 (0.7)	0.004	0.8 (0.2)	1.2 (0.2)	0.000
Period						
Up to January 9, 2021	574 (57.7)	1061 (59.1)	-0.027	204.1 (61.1)	326.9 (61.1)	0.000
January 10 to July 15, 2021	403 (40.5)	716 (39.9)	0.014	129.1 (38.7)	206.9 (38.7)	0.000
After July 15, 2021	17 (1.7)	19 (1.1)	0.056	0.8 (0.2)	1.2 (0.2)	0.000
CCI						
0	598 (60.2)	981 (54.6)	0.112	313.6 (93.9)	502.4 (93.9)	0.000
1-2	285 (28.7)	648 (36.1)	-0.159	19.6 (5.9)	31.4 (5.9)	0.000
3-4	85 (8.6)	132 (7.3)	0.044	0.8 (0.2)	1.2 (0.2)	0.000
>=5	26 (2.6)	35 (1.9)	0.045	0.0 (0.0)	0.0 (0.0)	0.000
Comorbidities						
Atrial fibrillation/undulation	60 (6.0)	84 (4.7)	0.060	0.0 (0.0)	0.0 (0.0)	0.000
Autoimmune disease	110 (11.1)	268 (14.9)	-0.115	4.2 (1.3)	6.8 (1.3)	0.000
Cancer	55 (5.5)	128 (7.1)	-0.065	0.8 (0.2)	1.2 (0.2)	0.000
Congestive heart failure	30 (3.0)	66 (3.7)	-0.037	0.0 (0.0)	0.0 (0.0)	0.000
COPD	109 (11.0)	269 (15.0)	-0.120	8.8 (2.6)	14.2 (2.6)	0.000
IHD or CVD	146 (14.7)	241 (13.4)	0.037	3.1 (0.9)	4.9 (0.9)	0.000
Renal disease	23 (2.3)	31 (1.7)	0.042	0.0 (0.0)	0.0 (0.0)	0.000
Diabetes + complications	18 (1.8)	34 (1.9)	-0.006	0.0 (0.0)	0.0 (0.0)	0.000
Diabetes w/o complications	159 (16.0)	315 (17.5)	-0.041	6.9 (2.1)	11.1 (2.1)	0.000
Dementia	37 (3.7)	56 (3.1)	0.033	0.0 (0.0)	0.0 (0.0)	0.000
Immunocompromised	14 (1.4)	23 (1.3)	0.011	0.8 (0.2)	1.2 (0.2)	0.000
RAAS inhibitors	284 (28.6)	644 (35.9)	-0.156	46.5 (13.9)	74.5 (13.9)	0.000
Diuretics	121 (12.2)	281 (15.6)	-0.100	5.8 (1.7)	9.2 (1.7)	0.000
F10-F19	27 (2.7)	44 (2.4)	0.017	0.0 (0.0)	0.0 (0.0)	0.000
F20-F29	117 (11.8)	112 (6.2)	0.194	10.4 (3.1)	16.6 (3.1)	0.000
F30-F39	434 (43.7)	971 (54.1)	-0.209	128.0 (38.3)	205.0 (38.3)	0.000

F40-F48	676 (68.0)	1199 (66.8)	0.027	266.4 (79.7)	426.6 (79.7)	0.000
Any of F04-F09, F50-F59, F60-F69, F70-F79, F80-F89, F90-F98	218 (21.9)	307 (17.1)	0.122	25.4 (7.6)	40.6 (7.6)	0.000
COVID-related hospitalization	11 (1.1)	17 (0.9)	0.016	2.9 (0.9)	0.9 (0.2)	0.068
All-cause 30-day hospitalization	125 (12.6)	206 (11.5)	0.034	21.9 (6.5)	28.8 (5.4)	0.036
COVID-related death	37 (3.7)	80 (4.5)	-0.037	1.5 (0.5)	4.6 (0.9)	-0.020